CoChat

GLP-1R Agonist Exendin-4 Protects Against Hemorrhagic Transformation Induced by rtPA After Ischemic Stroke via the Wnt/β-Catenin Signaling Pathway

Open access

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Abstract

Tissue plasminogen activator (tPA) is recommended by the FDA to dissolve intravascular clots after acute ischemic stroke (AIS). However, it may contribute to hemorrhagic transformation (HT). The Wnt/β-catenin signaling pathway plays an important role in regulating the blood–brain barrier (BBB) formation in the central nervous system. We explored whether glucagon-like peptide-1 receptor (GLP-1R) agonist exendin-4 (EX-4) reduces the risk of HT after rtPA treatment via the Wnt/β-catenin pathway by using a rat transient middle cerebral artery occlusion (MCAO) model in vivo and an oxygen–glucose deprivation plus reoxygenation (OGD/R) model in vitro. Our results showed that EX-4 attenuated neurological deficits, brain edema, infarct volume, BBB disruption, and rtPA-induced HT in ischemic stroke. EX-4 suppressed the production of ROS and the activation of MMP-9 to protect the integrity of the BBB by activating the Wnt/β-catenin signaling pathway. PRI-724, a selective inhibitor of β-catenin, was able to reverse the therapeutic effect of EX-4 in vivo and in vitro. Therefore, our results indicate that the GLP-1R agonist may be a potential therapeutic agent to decrease the risk of rtPA-induced HT after ischemic stroke via the Wnt/β-catenin signaling pathway.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12035-022-02811-9

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 EX-4 reduces neurologic deficit and infarct volume in rats after MCAO treated with rtPA. a In vivo, MCAO was performed by monofilament in rats. b Schematic diagram of the experimental design. The experimental groups were treated with vehicle, rtPA, rtPA + EX-4, or rtPA + EX-4 + PRI-724. c Rat performance on the neurologic deficit scores at 24 h after MCAO is shown in bar graphs (n = 25 rats/group). d Bar graphs show the brain water content at 24 h after MCAO (n = 4 rats/group). e Coronal sections immersed with TTC at 24 h after MCAO show infarct area (unstained regions). f Bar graphs show infarct volumes of each group (n = 5 rats/group). Data are shown as mean ± SD and analyzed by one-way ANOVA. *p < 0.05 vs. sham group, **p < 0.01 vs. sham group; #p < 0.05 vs. vehicle group, ##p < 0.01 vs. vehicle group
Fig. 1 EX-4 reduces neurologic deficit and infarct volume in rats after MCAO treated with rtPA. a In vivo, MCAO was performed by monofilament in rats. b Schematic diagram of the experimental design. The experimental groups were treated with vehicle, rtPA, rtPA + EX-4, or rtPA + EX-4 + PRI-724. c Rat performance on the neurologic deficit scores at 24 h after MCAO is shown in bar graphs (n = 25 rats/group). d Bar graphs show the brain water content at 24 h after MCAO (n = 4 rats/group). e Coronal sections immersed with TTC at 24 h after MCAO show infarct area (unstained regions). f Bar graphs show infarct volumes of each group (n = 5 rats/group). Data are shown as mean ± SD and analyzed by one-way ANOVA. *p < 0.05 vs. sham group, **p < 0.01 vs. sham group; #p < 0.05 vs. vehicle group, ##p < 0.01 vs. vehicle groupCC BY · PubMed Central
Fig. 2 EX-4 reduces rtPA-induced hemorrhagic transformation and BBB permeability after cerebral ischemia. a Coronal section shows the level of hemorrhage 24 h after MCAO. b Bar graphs show the quantification of hemorrhage volume measured by hemoglobin spectrophotometric assay (n = 5 rats/group). c Bar graphs show the content of the EB in the brain (n = 5 rats/group). d Coronal section shows the extravasation of the EB dye 24 h after MCAO. Data are shown as mean ± SD and analyzed by one-way ANOVA. **p < 0.01 vs. sham group; ##p < 0.01 vs. vehicle group
Fig. 2 EX-4 reduces rtPA-induced hemorrhagic transformation and BBB permeability after cerebral ischemia. a Coronal section shows the level of hemorrhage 24 h after MCAO. b Bar graphs show the quantification of hemorrhage volume measured by hemoglobin spectrophotometric assay (n = 5 rats/group). c Bar graphs show the content of the EB in the brain (n = 5 rats/group). d Coronal section shows the extravasation of the EB dye 24 h after MCAO. Data are shown as mean ± SD and analyzed by one-way ANOVA. **p < 0.01 vs. sham group; ##p < 0.01 vs. vehicle groupCC BY · PubMed Central
Fig. 3 EX-4 reduces rtPA-induced BBB damage after cerebral ischemia. a Histopathological changes tested by HE staining in infarcted cortex (original magnification × 400). b The MPO activity was detected in the infarcted lateral hemisphere (n = 4 rats/group). c–e Immunoblot images and quantitative data of the Occludin and Claudin-5 at 24 h after MCAO (n = 4 rats/group). f, g Immunoblot images and quantitative data of the ZO-1 at 24 h after MCAO (n = 4 rats/group). Data are shown as mean ± SD and analyzed by one-way ANOVA. *p < 0.05 vs. sham group, **p < 0.01 vs. sham group, ##p < 0.01 vs. vehicle group
Fig. 3 EX-4 reduces rtPA-induced BBB damage after cerebral ischemia. a Histopathological changes tested by HE staining in infarcted cortex (original magnification × 400). b The MPO activity was detected in the infarcted lateral hemisphere (n = 4 rats/group). c–e Immunoblot images and quantitative data of the Occludin and Claudin-5 at 24 h after MCAO (n = 4 rats/group). f, g Immunoblot images and quantitative data of the ZO-1 at 24 h after MCAO (n = 4 rats/group). Data are shown as mean ± SD and analyzed by one-way ANOVA. *p < 0.05 vs. sham group, **p < 0.01 vs. sham group, ##p < 0.01 vs. vehicle groupCC BY · PubMed Central
Fig. 4 Wnt/β-catenin signaling pathway plays an important role in rtPA-associated HT after MCAO in rats. a Representative images of β-catenin expression detected by immunohistochemical staining in the infarcted cortex (original magnification × 400). b, c Immunoblot images and quantitative data of β-catenin expression at 24 h after MCAO (n = 4 rats/group). d–f Immunoblot images and quantitative data of protein level of p-β-catenin and GSK-3β at 24 h after MCAO (n = 4 rats/group). Data are shown as mean ± SD and analyzed by one-way ANOVA. *p < 0.05 vs. sham group, **p < 0.01 vs. sham group, and ##p < 0.01 vs. vehicle group
Fig. 4 Wnt/β-catenin signaling pathway plays an important role in rtPA-associated HT after MCAO in rats. a Representative images of β-catenin expression detected by immunohistochemical staining in the infarcted cortex (original magnification × 400). b, c Immunoblot images and quantitative data of β-catenin expression at 24 h after MCAO (n = 4 rats/group). d–f Immunoblot images and quantitative data of protein level of p-β-catenin and GSK-3β at 24 h after MCAO (n = 4 rats/group). Data are shown as mean ± SD and analyzed by one-way ANOVA. *p < 0.05 vs. sham group, **p < 0.01 vs. sham group, and ##p < 0.01 vs. vehicle groupCC BY · PubMed Central
Fig. 5 EX-4 reduces the expression of MMP-9 in rtPA-associated HT after MCAO in rats. a Representative images of MMP-9 expression detected by immunofluorescence in the infarcted cortex (original magnification × 400). b, c Immunoblot images and quantitative data of the expression of MMP-9 at 24 h after MCAO (n = 4 rats/group). Data are shown as mean ± SD and analyzed by one-way ANOVA. *p < 0.05 vs. sham group, **p < 0.01 vs. sham group, and ##p < 0.01 vs. vehicle group
Fig. 5 EX-4 reduces the expression of MMP-9 in rtPA-associated HT after MCAO in rats. a Representative images of MMP-9 expression detected by immunofluorescence in the infarcted cortex (original magnification × 400). b, c Immunoblot images and quantitative data of the expression of MMP-9 at 24 h after MCAO (n = 4 rats/group). Data are shown as mean ± SD and analyzed by one-way ANOVA. *p < 0.05 vs. sham group, **p < 0.01 vs. sham group, and ##p < 0.01 vs. vehicle groupCC BY · PubMed Central
Fig. 6 Effect of EX-4 on protecting the BMEC viability and reducing the tPA-induced tight-junction protein damage in the OGD/R model in vitro. (A) The purity of primary BMECs was detected by immunofluorescence images (original magnification × 200). (B) Viability of the BMECs treated by different treatments was accessed by the CCK-8 kit in the OGD/R model in vitro (n = 5 in each group). c, d Apoptosis of BMECs treated by different treatments was tested by TUNEL assay in the OGD/R model in vitro (original magnification × 200). e–g Immunoblot images and quantitative data of the expression of the ZO-1, Occludin, and Claudin-5 in BMECs in the OGD/R model in vitro (n = 4 in each group). Data are shown as mean ± SD and analyzed by one-way ANOVA. *p < 0.05 vs. sham group, **p < 0.01 vs. sham group, ##p < 0.01 vs. vehicle group. + p < 0.05 between two groups and + + p < 0.01 between two groups
Fig. 6 Effect of EX-4 on protecting the BMEC viability and reducing the tPA-induced tight-junction protein damage in the OGD/R model in vitro. (A) The purity of primary BMECs was detected by immunofluorescence images (original magnification × 200). (B) Viability of the BMECs treated by different treatments was accessed by the CCK-8 kit in the OGD/R model in vitro (n = 5 in each group). c, d Apoptosis of BMECs treated by different treatments was tested by TUNEL assay in the OGD/R model in vitro (original magnification × 200). e–g Immunoblot images and quantitative data of the expression of the ZO-1, Occludin, and Claudin-5 in BMECs in the OGD/R model in vitro (n = 4 in each group). Data are shown as mean ± SD and analyzed by one-way ANOVA. *p < 0.05 vs. sham group, **p < 0.01 vs. sham group, ##p < 0.01 vs. vehicle group. + p < 0.05 between two groups and + + p < 0.01 between two groupsCC BY · PubMed Central
Fig. 7 Wnt/β-catenin signaling pathway plays an important role in the BMECs rtPA-induced OGD/R model in vitro. a Representative images of β-catenin and Claudin-5 expression detected by immunofluorescence (original magnification × 200). b, c Immunoblot images and quantitative data of the expression of p-β-catenin, β-catenin, and GSK-3β 24 h after MCAO (n = 4 in each group). Data are shown as mean ± SD and analyzed by one-way ANOVA. **p < 0.01 vs. sham group; ##p < 0.01 vs. vehicle group. + p < 0.05 between two groups, + + p < 0.01 between two groups
Fig. 7 Wnt/β-catenin signaling pathway plays an important role in the BMECs rtPA-induced OGD/R model in vitro. a Representative images of β-catenin and Claudin-5 expression detected by immunofluorescence (original magnification × 200). b, c Immunoblot images and quantitative data of the expression of p-β-catenin, β-catenin, and GSK-3β 24 h after MCAO (n = 4 in each group). Data are shown as mean ± SD and analyzed by one-way ANOVA. **p < 0.01 vs. sham group; ##p < 0.01 vs. vehicle group. + p < 0.05 between two groups, + + p < 0.01 between two groupsCC BY · PubMed Central
Fig. 8 EX-4 reduces rtPA-associated MMP-9 activation in the BMECs OGD/R model in vitro. a Representative images of MMP-9 and Claudin-5 expression detected by immunofluorescence in the BMECs OGD/R model in vitro (original magnification × 200). b, c Immunoblot images and quantitative data of the expression of MMP-9 in the BMECs OGD/R model in vitro (n = 4 in each group). Data are shown as mean ± SD and analyzed by one-way ANOVA. **p < 0.01 vs. sham group; ##p < 0.01 vs. vehicle group
Fig. 8 EX-4 reduces rtPA-associated MMP-9 activation in the BMECs OGD/R model in vitro. a Representative images of MMP-9 and Claudin-5 expression detected by immunofluorescence in the BMECs OGD/R model in vitro (original magnification × 200). b, c Immunoblot images and quantitative data of the expression of MMP-9 in the BMECs OGD/R model in vitro (n = 4 in each group). Data are shown as mean ± SD and analyzed by one-way ANOVA. **p < 0.01 vs. sham group; ##p < 0.01 vs. vehicle groupCC BY · PubMed Central
Fig. 9 EX-4 reduces rtPA-associated ROS production in BMECs 24 h after OGD/R in vitro. a Representative images of ROS expression detected by immunofluorescence in BMECs 24 h after OGD/R in vitro (original magnification × 200). b, c Flow cytometry analysis of ROS in BMECs 24 h after OGD/R in vitro. Bar graphs illustrate the quantitative analysis (n = 4 in each group). Data are shown as mean ± SD and analyzed by one-way ANOVA. **p < 0.01 vs. sham group; ##p < 0.01 vs. vehicle group
Fig. 9 EX-4 reduces rtPA-associated ROS production in BMECs 24 h after OGD/R in vitro. a Representative images of ROS expression detected by immunofluorescence in BMECs 24 h after OGD/R in vitro (original magnification × 200). b, c Flow cytometry analysis of ROS in BMECs 24 h after OGD/R in vitro. Bar graphs illustrate the quantitative analysis (n = 4 in each group). Data are shown as mean ± SD and analyzed by one-way ANOVA. **p < 0.01 vs. sham group; ##p < 0.01 vs. vehicle groupCC BY · PubMed Central
Fig. 10 A summary diagram to show the mechanisms of HT after ischemic stroke treated by rtPA via Wnt/β-catenin signaling pathway. I/R: ischemic/reperfusion. rtPA: tissue-type plasminogen activator. ROS: reactive oxygen species. MMP-9: matrix metalloproteinase-9. GSK-3β: glycogen synthase kinase-3β. ZO-1: zonula occludens-1
Fig. 10 A summary diagram to show the mechanisms of HT after ischemic stroke treated by rtPA via Wnt/β-catenin signaling pathway. I/R: ischemic/reperfusion. rtPA: tissue-type plasminogen activator. ROS: reactive oxygen species. MMP-9: matrix metalloproteinase-9. GSK-3β: glycogen synthase kinase-3β. ZO-1: zonula occludens-1CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 57 references

Cited by

See all 28

Metadata

Authors
Liu, C., Sun, S., Xie, J., Li, H., Li, T., Wu, Q., Zhang, Y., Bai, X., Wang, J., Wang, X., Li, Z., & Wang, W.
Affiliations
  • Tongji Hospital (CN)
  • Zhengzhou University (CN)
  • Brigham and Women's Hospital (US)
Corresponding author
  • Li, Zhanfei
  • Wang, Wei
Venue
Molecular Neurobiology
Published
2022-03-31
Volume
59
Issue
6
Pages
3649-3664
ISSN
  • 0893-7648 (ISSN-L)
  • 1559-1182
OpenAlex
W4220980256
Cited by
28
References
57
Citations by year
2026: 6 · 2025: 8 · 2024: 3 · 2023: 6 · 2022: 5
FWCI
3.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Neurobiology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
National Natural Science Foundation of China (81801174)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
Keywords
exendin-4, GLP-1 receptor agonists, hemorrhagic transformation, acute ischemic stroke, tissue plasminogen activator, Wnt/β-catenin signaling, blood-brain barrier disruption, MMP-9, reactive oxygen species, PRI-724, transient middle cerebral artery occlusion, oxygen-glucose deprivation/reoxygenation, neuroprotection
MeSH terms
Exenatide, Ischemic Stroke, Animals, Hemorrhage, Tissue Plasminogen Activator, Stroke, beta Catenin, Rats, Wnt Signaling Pathway

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1R Agonist Exendin-4 Protects Against Hemorrhagic Transformation Induced by rtPA After Ischemic Stroke via the Wnt/β-Catenin Signaling Pathway. https://app.cochat.ai/papers/10.1007/s12035-022-02811-9
The paper
Liu, C., Sun, S., Xie, J., Li, H., Li, T., Wu, Q., Zhang, Y., Bai, X., Wang, J., Wang, X., Li, Z., & Wang, W. (2022). GLP-1R Agonist Exendin-4 Protects Against Hemorrhagic Transformation Induced by rtPA After Ischemic Stroke via the Wnt/β-Catenin Signaling Pathway. Molecular Neurobiology. https://doi.org/10.1007/s12035-022-02811-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.